- Research & Clinical Trials
- Cutting-Edge Alzheimer’s Research
- Successful Aging Program
- The 90+ Study
- Down Syndrome Program
- Clinical Trials
- Training Grant Preceptors
Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study)
Lead researcher: Aimee L. Pierce, MD
Location: UCI Campus (UCI MIND Gottschalk Medical Plaza, ICTS in Hewitt Hall, Newport Diagnostic Center, CARE Clinic in Laguna Woods)
Purpose: To evaluate whether immunization treatment with solanezumab versus placebo will slow cognitive decline in individuals showing the presence of elevated protein called amyloid on a brain scan.
Eligibility: Male and female participants, ages 65-85 years old, with evidence of elevated brain amyloid pathology on a brain scan.
Time commitment: Screening phase (up to 90 days) and treatment phase (48 visits over the course of 168 weeks or ~3 years)
Benefits: You may or may not receive any benefit from being in this study. If you are in the group that receives the study drug, solanezumab, and it proves to treat your condition better than placebo, you may benefit from participating in the study, but this cannot be guaranteed. The information collected from this study may increase knowledge regarding the treatment of Alzheimer’s disease and help people in the future.
Compensation: Participants are eligible to receive the following compensation in cash during the course of this study:
- $100 for each completed MRI scan; there are 4 MRI scans ($400 max).
- $100 for each completed PET scan; there are 2 PET scans ($200 max).
- $100 for each completed lumbar puncture; there are two optional lumbar punctures ($200 max).
- $50 for each infusion visit requiring infusion; there are 42 infusion visits in this study ($2100 max).
The grand total compensation for this study is a maximum of $2900 in cash. Participants will also be reimbursed $40 in cash for travel-related expenses for each visit required for the study.